CI
TEVA icon

Carroll Investors’s Teva Pharmaceuticals TEVA Stock Holding History

Carroll Investors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-437
Closed -$4K – 149
2022
Q1 		$4K Hold
437
– – ﹤0.01% 150
2021
Q4 		$3K Buy
+437
New +$3.94K ﹤0.01% 173

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Carroll Investors's TEVA Position: Q2 2022 in Review

Carroll Investors sold out of Teva Pharmaceuticals (TEVA) in Q2 2022, closing a stake of 437 shares — an estimated $4K sold.

Carroll Investors first reported a position in TEVA in Q4 2021 and held it in 2 quarters. The position peaked at $4K in Q1 2022. 456 funds tracked by Wall St. Rank hold TEVA as of Q2 2022.

  • Carroll Investors reported no remaining Teva Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Carroll Investors sold 437 Teva Pharmaceuticals shares in Q2 2022, an estimated $4K.
  • Carroll Investors first reported a position in Teva Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Carroll Investors's Teva Pharmaceuticals position peaked at $4K in Q1 2022.
  • 456 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2022.

Based on Carroll Investors's 13F filing for Q2 2022, filed 26 Jul 2022.